In 1993 a high-ranking FDA official, Robert Temple, issued a report on how the burgeoning device industry could conduct more rigorous clinical trials.

FORBES: On The Cover/Top Stories

On a recent call with patient advocates about muscular dystrophy drugs, Robert Temple, a top FDA official, explained that in some cases surrogates can be enough to get approved.

FORBES: Merck's Big Vytorin Study Could Change Rules For New Cholesterol Drugs

Mentions Robert Temple and Wayne Jonas.

NEWYORKER: The Power of Nothing

"In terms of scale, it's not soon or ever to be repeated, " said Dr. Robert Whitaker, a Temple University pediatrician who was a study co-author.

MSN: Living in poor neighborhood can hurt health

TEMPLE-RASTON: Robert Hormats is vice chairman of Goldman Sachs International.

NPR: Can The Global Crisis Wait For A New President?